Mesoblast's trial was in treating COVID-19 ARDS Which had a mortality rate of 42% in <65's.
Talking about influenza, you highlight the large market Novartis are looking at treating with Rem-l: all cause ARDS (which influenza is the leading cause). On average around 67,000 people <65 in the US die annually from all cause ARDS, which has a similar mortality rate of ~40%.
If Rem-l + dex proves to be just as effective in treating all cause ARDS in <65s as it has been with covid ARDS, it has the potential to save 52,000 lives annually and become a huge source of revenue for Mesoblast and Novartis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122485/
Ann: Appendix 4C Quarterly Activity Report, page-231
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |